naringenin and ER-Negative PR-Negative HER2-Negative Breast Cancer

naringenin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Burade, V; Goswami, S; Pateliya, B	1

Other Studies

1 other study(ies) available for naringenin and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo. European journal of pharmacology, 2021, Jan-15, Volume: 891 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Female; Flavanones; Humans; Interleukin-1beta; Male; Metformin; Mice, Inbred BALB C; Mice, Nude; Necrosis; Triple Negative Breast Neoplasms; Troponin I; Tumor Burden; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays	2021

Article

Year

Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo.

European journal of pharmacology, 2021, Jan-15, Volume: 891

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Female; Flavanones; Humans; Interleukin-1beta; Male; Metformin; Mice, Inbred BALB C; Mice, Nude; Necrosis; Triple Negative Breast Neoplasms; Troponin I; Tumor Burden; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays

2021